Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-10-20

Clinical Trial Update: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [Phase 3]

View source ↗

Summary

Phase 3 trial update for tirzepatide in adults with type 2 diabetes not controlled by diet and exercise, completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2021-10-20